Cetirizine Hydrochloride Patent Expiration
Cetirizine Hydrochloride is Used for the treatment of acute urticaria and angioedema by increasing peak plasma concentration through intravenous injection. It was first introduced by Johnson And Johnson Consumer Inc Mcneil Consumer Healthcare Div
Cetirizine Hydrochloride Patents
Given below is the list of patents protecting Cetirizine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zerviate |
US9254286 (Pediatric) | Ophthalmic formulations of cetirizine and methods of use | Jan 09, 2033 | Harrow Eye |
| Zerviate | US9254286 | Ophthalmic formulations of cetirizine and methods of use | Jul 09, 2032 | Harrow Eye |
| Zerviate |
US8829005 (Pediatric) | Ophthalmic formulations of cetirizine and methods of use | Sep 15, 2030 | Harrow Eye |
| Zerviate | US8829005 | Ophthalmic formulations of cetirizine and methods of use | Mar 15, 2030 | Harrow Eye |
| Zerviate | US9750684 | Ophthalmic formulations of cetirizine and methods of use | Mar 15, 2030 | Harrow Eye |
| Zerviate | US9993471 | Ophthalmic formulations of cetirizine and methods of use | Mar 15, 2030 | Harrow Eye |
| Quzyttir | US8263581 | Non-sedating antihistamine injection formulations and methods of use thereof | Feb 28, 2030 | Jdp |
| Quzyttir | US8314083 | Non-sedating antihistamine injection formulations and methods of use thereof | Feb 28, 2030 | Jdp |
| Quzyttir | US8513259 | Non-sedating antihistamine injection formulations and methods of use thereof | Feb 11, 2030 | Jdp |
| Quzyttir | US9119771 | Non-sedating antihistamine injection formulations and methods of use thereof | Feb 11, 2030 | Jdp |
| Quzyttir | US9180090 | Non-sedating antihistamine injection formulations and methods of use thereof | Feb 11, 2030 | Jdp |
| Children's Zyrtec Allergy | US6455533 | Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin |
Jul 02, 2018
(Expired) | Kenvue Brands |
| Children's Zyrtec Hives Relief | US6455533 | Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin |
Jul 02, 2018
(Expired) | Kenvue Brands |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Cetirizine Hydrochloride's patents.
Latest Legal Activities on Cetirizine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Cetirizine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 May, 2024 | US8314083 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Feb, 2024 | US8263581 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 09 Aug, 2023 | US9254286 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Feb, 2023 | US9119771 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Mar, 2022 | US8829005 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Nov, 2021 | US9993471 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Apr, 2021 | US8513259 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Apr, 2021 | US8314083 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Apr, 2021 | US9119771 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Feb, 2021 | US9750684 |
Cetirizine Hydrochloride's Family Patents
